We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Baseline Characteristics of Participants in the ASPREE (ASPirin in Reducing Events in the Elderly) Study.
- Authors
McNeil, John J.; Woods, Robyn L.; Nelson, Mark R.; Murray, Anne M.; Reid, Christopher M.; Kirpach, Brenda; Storey, Elsdon; Shah, Raj C.; Wolfe, Rory S.; Tonkin, Andrew M.; Newman, Anne B.; Williamson, Jeff D.; Lockery, Jessica E.; Margolis, Karen L.; Ernst, Michael E.; Abhayaratna, Walter P.; Stocks, Nigel; Fitzgerald, Sharyn M.; Trevaks, Ruth E.; Orchard, Suzanne G.
- Abstract
<bold>Background: </bold>There are no primary prevention trials of aspirin with relevant geriatric outcomes in elderly people. ASPirin in Reducing Events in the Elderly (ASPREE) is a placebo-controlled trial of low-dose aspirin that will determine whether 5 years of daily 100-mg enteric-coated aspirin extends disability-free and dementia-free life in a healthy elderly population and whether these benefits outweigh the risks.<bold>Methods: </bold>Set in primary care, this randomized double-blind placebo-controlled trial has a composite primary endpoint of death, incident dementia or persistent physical disability. Participants aged 70+ years (non-minorities) or 65+ years (U.S. minorities) were free of cardiovascular disease, dementia, or physical disability and without a contraindication to, or indication for, aspirin. Baseline data include physical and lifestyle, personal and family medical history, hemoglobin, fasting glucose, creatinine, lipid panel, urinary albumin:creatinine ratio, cognition (3MS, HVLT-R, COWAT, SDMT), mood (CES-D-10), physical function (gait speed, grip strength), Katz activities of daily living and quality of life (SF-12).<bold>Results: </bold>Recruitment ended in December 2014 with 16,703 Australian and 2,411 U.S. participants, a median age of 74 (range 65-98) years and 56% women. Approximately 55% of the U.S. cohort were from minority groups; 9% of the total cohort. Proportions with hypertension, overweight, and chronic kidney disease were similar to age-matched populations from both countries although lower percentages had diabetes, dyslipidemia, and osteoarthritis.<bold>Discussion: </bold>Findings from ASPREE will be generalizable to a healthier older population in both countries and will assess whether the broad benefits of daily low-dose aspirin in prolonging independent life outweigh the risks.
- Subjects
AUSTRALIA; UNITED States; ASPIRIN; HEALTH of older people; NONSTEROIDAL anti-inflammatory agents; DEMENTIA prevention; CARDIOVASCULAR disease prevention; AGING; CARDIOVASCULAR diseases; COMPARATIVE studies; DEMENTIA; GERIATRIC assessment; DOSE-effect relationship in pharmacology; ENZYME inhibitors; RESEARCH methodology; MEDICAL cooperation; ORAL drug administration; PEOPLE with disabilities; PROGNOSIS; QUALITY of life; RESEARCH; RESEARCH funding; STATISTICAL sampling; ACTIVITIES of daily living; EVALUATION research; RANDOMIZED controlled trials; DISEASE incidence; BLIND experiment
- Publication
Journals of Gerontology Series A: Biological Sciences & Medical Sciences, 2017, Vol 72, Issue 11, p1586
- ISSN
1079-5006
- Publication type
journal article
- DOI
10.1093/gerona/glw342